MELBOURNE, Australia–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/PPCB?src=hash” target=”_blank”gt;#PPCBlt;/agt;–Propanc
Biopharma, Inc. (OTCQB:PPCB) (“Propanc”), a biopharmaceutical
company developing new cancer treatments for patients suffering from
recurring and metastatic cancer, announced today that its Chief
Executive Officer, James Nathanielsz, has been invited to present at the
31st Annual ROTH Conference being held on March 17 – 19, 2019
at the Ritz Carlton, Laguna Niguel located in Orange County, California.
The conference will feature presentations from public and private
companies across a variety of industry sectors and is one of the largest
of its kind in the US. Last year, the ROTH Conference hosted close to
550 participating companies and more than 4,700 attendees, including
institutional investors, analysts, family offices and high net worth
Mr. Nathanielsz is scheduled to present in one-on-one meetings with
institutional analysts and investors throughout the day on March 19. He
will be discussing Propanc’s plans for advancing its lead product, PRP,
towards human trials this year.
ROTH will host a pre-recorded webcast of Propanc’s presentation, which
will be available on the conference website at http://wsw.com/webcast/roth33/ppcb/
beginning on March 11.
Investors and potential partners attending the conference who wish to
meet with Propanc’s management can contact their ROTH representative.
For those not planning to attend the conference, please contact Lisa
DeScenza to set up a call with Mr. Nathanielsz to learn more about
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the “Company”) is developing a novel approach
to prevent recurrence and metastasis of solid tumors by using pancreatic
proenzymes that target and eradicate cancer stem cells in patients
suffering from pancreatic, ovarian and colorectal cancers. For more
information, please visit www.propanc.com.
Propanc Biopharma’s Pancreatic Enzyme Therapy Platform
Propanc Biopharma’s novel proenzyme therapy is based on the science that
enzymes stimulate biological reactions in the body, especially enzymes
secreted by the pancreas. These pancreatic enzymes could represent the
body’s primary defense against cancer.
To view the Company’s “Mechanism of Action” video on anti-cancer product
candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video.
All statements other than statements of historical facts contained in
this press release are “forward-looking statements,” which may often,
but not always, be identified by the use of such words as “may,”
“might,” “will,” “will likely result,” “would,” “should,” “estimate,”
“plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,”
“believe,” “seek,” “continue,” “target” or the negative of such terms or
other similar expressions. These statements involve known and unknown
risks, uncertainties and other factors, which may cause actual results,
performance or achievements to differ materially from those expressed or
implied by such statements. These factors include uncertainties as to
the Company’s ability to continue as a going concern absent new debt or
equity financings; the Company’s current reliance on substantial debt
financing that it is unable to repay in cash; the Company’s ability to
successfully remediate material weaknesses in its internal controls; the
Company’s ability to reach research and development milestones as
planned and within proposed budgets; the Company’s ability to control
costs; the Company’s ability to obtain adequate new financing on
reasonable terms; the Company’s ability to successfully develop PRP, its
lead product candidate; the Company’s ability to obtain and maintain
patent protection; the Company’s ability to recruit employees and
directors with accounting and finance expertise; the Company’s
dependence on third parties for services; the Company’s dependence on
key executives; the impact of government regulations, including FDA
regulations; the impact of any future litigation; the availability of
capital; changes in economic conditions, competition; and other risks,
including, but not limited to, those described in the Company’s
Registration Statement on Form S-1, filed with the U.S. Securities and
Exchange Commission (the “SEC”) on February 25, 2019, and in the
Company’s other filings and submissions with the SEC. These
forward-looking statements speak only as of the date hereof and the
Company disclaims any obligations to update these statements except as
may be required by law.
Investor Relations and Media:
Vice President, Integrated Communications